Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Decreases By 42.9%

Vincerx Pharma, Inc. (NASDAQ:VINC) was the recipient of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 419,600 shares, a drop of 42.9% from the November 30th total of 735,400 shares. Based on an average daily volume of 702,800 shares, the days-to-cover ratio is currently 0.6 days.

Hedge Funds Weigh In On Vincerx Pharma

A hedge fund recently bought a new stake in Vincerx Pharma stock. Armistice Capital LLC acquired a new position in Vincerx Pharma, Inc. (NASDAQ:VINC) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,988,000 shares of the company’s stock, valued at approximately $1,610,000. Armistice Capital LLC owned approximately 6.70% of Vincerx Pharma as of its most recent filing with the Securities and Exchange Commission (SEC). 44.02% of the stock is currently owned by institutional investors.

Vincerx Pharma Stock Down 1.7 %

NASDAQ VINC opened at $0.18 on Friday. The stock has a market capitalization of $6.19 million, a P/E ratio of -0.18 and a beta of 1.48. Vincerx Pharma has a 52-week low of $0.18 and a 52-week high of $9.37. The firm has a 50-day moving average price of $0.28 and a 200 day moving average price of $0.53.

Analysts Set New Price Targets

Separately, Leerink Partners lowered their price objective on shares of Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.